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ABSTRACT
In December 2019, several cases of pneumonia of unknown origin were reported in the 
city of Wuhan, province of Hubei, China. The pathogen was named as severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) and the disease was named coronavirus disease 2019 
(COVID-19). Acute phase reactans (APRs) are critical in the early diagnosis, treatment, 
and for monitoring the progression of COVID-19. Seventy two patients were included in 
the study and infections confirmed by real-time reverse transcription polymerase chain 
reaction. Clinical parameters, the level of APFs and D-dimer were assessed and results were 
retrived from the patients’ medical records. Chest computed tomography (CT) findings were 
described for each patient and they were divided into two groups, with or without COVID-19 
pneumonia. The correlation between APRs and CT findings and the patients’ prognosis were 
evaluated. Twenty eight (38.8%) of the 72 patients were female and 44 (61.2%) were male. 
The most common symptom was cough (43%) and the most common associated chronic 
disease was hypertension (12.5%). Thirty (41.6%) patients had completely normal chest 
CT, while 42 (58.4%) patients had typical findings in terms of COVID-19 pneumonia. C 
reactive protein (CRP), lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), 
ferritin, procalcitonin and D-Dimer levels were statistically significantly higher in patients 
with pneumonia than in those without pneumonia and these parameters were also statistically 
significantly higher in patients with severe illness. In conclusion, CRP, LDH, ESR, ferritin, 
and D-Dimer were associated with severe COVID-19 pneumonia. These biomarkers can be 
used to evaluate the prognosis to predict the clinical course of disease, allowing a proper 
management and treatment of the patients. 
KEYWORDS: Acute phase reactans. SARS-CoV-2. COVID-19. Computed tomography. 
Pneumonia. 
INTRODUCTION
In December 2019, several cases of pneumonia of unknown origin were reported 
in the city of Wuhan, province of Hubei, China1. In January 2020, this pathogen 
was identified by Chinese scientists as a more infectious coronavirus, similar to 
the ones of the severe acute respiratory syndrome coronavirus (SARS-CoV) and 
the Middle East respiratory syndrome coronavirus (MERS-CoV)2. In February 
2020, this novel coronavirus was named as severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of 
Viruses, and the disease was named coronavirus disease 2019 (COVID-19) by the 
World Health Organization (WHO)1. SARS-CoV-2 has affected more than 183 
countries and territories in a short time due to its high transmission, and a pandemic 
was declared by the WHO in March 2020. SARS-CoV-2 is transmitted from 
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human to human by multiple means, namely, by droplets, 
aerosols, and fomites3. Although SARS-CoV-2 mostly 
causes mild symptoms, such as fever, cough, myalgia, 
and fatigue, it may trigger serious clinical complications 
such as pneumonia, pulmonary edema, acute respiratory 
distress syndrome (ARDS), multiple organ failure and 
septic shock3. SARS‐CoV‐2 enters the host cells by the 
binding with the angiotensin-converting enzyme 2 (ACE2) 
receptor4. ACE2 is present in many cell types and tissues, 
including the lungs, heart, blood vessels, kidneys, liver and 
gastrointestinal tract. It is present in epithelial cells, in some 
specific cell in certain tissues, creating a protective barrier4. 
When SARS-CoV-2 binds to ACE2, it prevents ACE2 from 
performing its normal function of regulating angiotensin 2 
signaling. Thus, ACE2 action is inhibited, and abundant 
angiotensin 2 is produced, leading to tissue damage. 
Therefore, ACE2 contributes to tissue damage, especially in 
the lungs and heart in patients with COVID-195. The virus 
reaches the lungs after entering the nose or mouth, and it 
can cause respiratory problems, such as pneumonia2. The 
reverse transcription polymerase chain reaction (RT-PCR) 
test is a real-time RT-PCR (rRT-PCR) test to qualitatively 
detect nucleic acid from SARS-CoV-2 in the upper and 
the lower respiratory specimens (e.g., nasopharyngeal and 
oropharyngeal swabs), providing evidence for a definitive 
diagnosis of COVID-196. The shortage of kits and the false 
negative rate of RT-PCR results (2-29%) cause delays in the 
early diagnosis and treatment of patients6. This situation led 
clinicians to request the chest computed tomography (CT) 
scans to reveal the involvement of lungs and to achieve an 
early treatment in patients suspected to have COVID-19, 
especially those with complaints such as fever, dyspnea 
and cough3. Typical findings, such as peripheral multifocal 
ground glass opacities, a disorganized paving pattern and 
the presence of a reverse halo have been described in the 
chest CT scans of patients with a definitive diagnosis 
of COVID-19. Therefore, chest CT plays a critical and 
significant role in the early diagnosis and treatment of 
COVID-19, as the mortality rates of COVID-19 pneumonia 
are high2,3. 
Acute phase reactants (APRs) are inflammation 
biomarkers that exhibit significant changes in their 
serum concentrations during inflammation caused by 
infectious and noninfectious conditions. APRs are used 
for the early diagnosis, to distinguish infectious diseases 
from noninfectious ones and to evaluate the response 
to treatment7. Important APRs include the erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), lactate 
dehydrogenase (LDH), fibrinogen, ferritin, procalcitonin, 
D-dimer and troponin7. The concentrations of all these 
positive APRs increase in the serum during inflammation. 
D-Dimer is a cross-linked fibrin breakdown product and a 
small fragment of protein that is present in the blood after 
a clot breaks down during fibrinolysis.
Recent studies have shown that elevated D-dimer levels 
indicate a poor prognosis in patients with COVID-198,9. 
Early diagnosis and evaluation of the disease severity 
in patients infected with SARS-CoV-2 is critical for the 
medical management and treatment. Our aim was to 
evaluate the relationship between laboratory findings (APRs 
and D-dimer) in patients with and without COVID-19 
pneumonia. In addition, we investigated the relationship 
between laboratory values and the prognosis of these 
patients.
MATERIALS AND METHODS
This study was approved by the institutional review 
board of the Ondokuz Mayis University Faculty of Medicine 
and the Ethics Committee of this hospital. The stsudy 
procedures were in accordance with the Declaration of 
Helsinki (2020/340). In addition, approval of the study was 
obtained from the Republic of Turkey Ministry of Health. 
This study did not have any funding. 
Study population
This retrospective study included 72 patients (28 female, 
44 male) who were diagnosed with COVID-19 by RT-PCR. 
They sought the emergency department presenting 
with symptoms such as fever, dry cough, weakness and 
underwent chest CT on admission to the hospital. All 
patients included in the study were newly diagnosed 
and untreated at the time of admission to the emergency 
department of the Ondokuz Mayis University Faculty of 
Medicine in Samsun, Turkey. The medical information 
of all patients were retrospectively retrieved from their 
medical records and evaluated. Age, gender, comorbidities, 
symptoms on admission, levels of APRs and D-dimer and 
chest CT findings were collected for each patient before the 
treatment. Blood samples (APRs and D-dimer) were taken 
on admission to the hospital for each patient. Patients with 
underlying diseases, such as tuberculosis, lung carcinomaor 
other chronic lung diseases were excluded from the study. 
All patients were treated with the same treatment 
protocol according to the COVID-19 guidelines of 
the Turkish Ministry of Health (hydroxychloroquine, 
azithromycin, favipiravir and enoxaparin sodium) between 
January and June 2020. 
The COVID-19 patients were divided into two groups 
according to the disease severity: mild or severe. Patients 
were considered to have mild disease if they received 
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medical treatment and were isolated at home or in a hospital 
and they were subsequently discharged. Patients were 
considered to have severe disease if they received oxygen 
therapy and medical care during hospitalization or were 
admitted to the intensive care unit (ICU) with only oxygen 
support and/or required intubation and respiratory support. 
We evaluated the relationship between the levels of APRs 
and the prognosis of the patients.
Image acquisition and analysis 
During the first admission to the hospital, chest CT 
(Canon, Aquilion Prime SP, Canon Medical Systems, Japan) 
was performed in patients suspected of having pneumonia 
due to COVID-19 and presenting with symptoms such as 
dyspnea, cough and fever. Unenhanced chest CT scans were 
obtained with a low dose technique (mA, kV: 150, slice 
thickness: 1 mm) in the CT unit, which was specifically 
located in an isolated area of the emergency department. 
The chest CT scans of each patient were independently 
evaluated by two experienced radiologists (A.T.S. and 
M.E.) in thoracic radiology. Chest CT findings such as 
ground glass opacification, consolidation, disorganized 
paving pattern, and reverse halo, which are typically 
described in COVID-19 pneumonia, were considered 
to be indicative of COVID-19 pneumonia. Patients with 
normal chest imaging were allocated in the group without 
pneumonia. All laboratory tests were collected on the same 
date that the chest CT was performed. We investigated 
whether there were associations between APRs and 
D-dimer values in patients with (group A) and without 
pneumonia (Group B).
Statistical analysis
The SPSS Statistics package, version 21 for Windows 
(IBM SPSS Inc., Armonk, NY, USA) was used to perform 
all statistical analyses. The normality of the variables 
distribution was examined by the Shapiro–Wilk test. 
Descriptive analyses results were expressed as the mean 
and standard deviations for normally distributed variables. 
The median (minimum-maximum values) were used for 
non-normally distributed variables. Categorical variables 
were expressed as percentages. No more than one blood 
sample was taken from all patients. The student t-test was 
used to compare normally distributed variables, and the 
Mann–Whitney U test was used to compare non-normally 
distributed variables. In the comparisons of categorical 
variables, the chi-square test or the Fisher’s exact test were 
used. A value of p < 0.05 was considered significant in all 
statistical analyses.
RESULTS
From the total of 72 patients (mean age: 45.08 ± 17.1 years), 
28 (38.8%) were female, and 44 (61.2%) were male. The mean 
age of male patients was higher than that of female patients 
(46.43 ± 16.50 years vs. 44.23 ± 17.60 years, p=0.59). The 
most common symptom of the patients was cough (43%), 
and the second most common symptom was fever (20.8%). 
Of the 72 patients, 23 (31.9%) had a history of one or more 
chronic diseases or a history of cancer treatment. The most 
commonly reported chronic disease was hypertension (HT) 
(12.5%). The demographic findings are shown in Table 1.
During the first admission to the hospital, 30 (41.6%) 
patients had completely normal chest CT scans, while 
42 (58.4%) patients had typical findings of COVID-19 
pneumonia. The age of patients who had pneumonia was 
significantly higher than that of those with normal chest CT 
(51.5 ± 15.8 years vs. 36 ± 14.5 years, p<0.001). Of the 
Table 1 - Demographic data of the 72 patients with COVID-19. 
Patients’ demographic data Number of cases 
Comorbid 
conditions
Hypertension 9 (12.5 %)
Previous carcinoma history 7 (9.7 %)
Diabetes mellitus 5 (6.9 %)
Coronary artery disease 4 (5.5 %)
COPD 3 (4.1 %)
Hyperlipidemia 2 (2.7 %)
Cerebrovascular disease 2 (2.7 %)
Chronic kidney disease 1 ( 1.3 %)
Other comorbidities 2 (2.7 %)




Cough 31 (43 %)
Fever 15 (20.8 %)
Dyspnea 6 (8.3 %)
Chest pain 4 (5.5 %)
Fatigue weakness 3 (4.1 %)
Diarrhea 2 (2.7 %)







Female 46.43 ± 16.50 
Male 44.23 ± 17.60
COVID-19 = Coronavirus disease 2019; COPD = Chronic 
obstructive pulmonary disease.
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42 patients with pneumonia, 15 were female (35.7%), and 
27 were male (64.3%). Signs of pneumonia infiltration were 
more frequently found in men. The age of female patients 
who had pneumonia was higher than that of male patients 
(55.2 ± 14.8 years vs. 49.5 ± 16.3 years, p=0.51). The age 
of female patients who had pneumonia was significantly 
higher than those of female patients without pneumonia 
(55.2 ± 14.8 years vs. 36.2 ± 12.1 years, p=0.001). In the 
same way, the age of the male patients who had pneumonia 
was significantly higher than those of male patients without 
pneumonia (49.5 ± 16.3 years vs. 35.8 ± 16.6 years, p=0.01). 
The demographic findings of the patients with or without 
pneumonia are shown in Table 2. Among the 42 patients 
with pneumonia, the infiltration was bilateral in 34 patients 
(47.2%) (12 females, 22 males) (Figure 1), located only on 
the left side in 3 patients (4.2%) (1 female, 2 males), and 
in the right side in 5 patients (6.9%) (2 females, 3 males) 
(Figure 2). The most common chest CT findings in patients 
with pneumonia were bilateral, peripheral, and basal, with 
a predominance of ground glass opacities (GGOs) and/or 
consolidation.
Considering the total of 72 patients, 46 (63.8%) had 
mild disease, and 26 (36.2%) had severe disease. Of the 
46 patients with mild disease, 11 were isolated at treated 
at home, and 35 were treated in a pandemic service. Of 
the 26 patients with severe disease, 18 received oxygen 
supplementation in addition to medication in the pandemic 
service, and 8 were intubated and treated in the ICU. 
Despite the hospitalization and treatment, three of these 
eight patients (1 female, 2 males), including a 38-year-old 
male patient with a history of esophageal carcinoma; 
a 65-year-old male patient with a history of HT; and a 
63-year-old female patient with a history of HT, coronary 
artery disease and cerebrovascular disease, died in the ICU 
(4.2%). The other 69 (95.8%) patients were discharged 
from the hospital. 
The laboratory findings and statistical results of patients 
with pneumonia in group A and without pneumonia in 
group B are shown in Table 3. Only the necessary APRs 
were assessed and no unnecessary blood tests were 
performed. All APR samples were taken considering 
the signs and symptoms of the patients. In addition, this 
procedure did not affect the comparison between groups.
The laboratory findings of the patients and the statistical 
results of those with severe and mild disease are shown in 
Table 4.
Table 2 - Demographic data of the 72 patients with COVID-19 divided into two groups: with (42) or without pneumonia (30). 
Patients’ demographics With pneumonia Without pneumonia p
Gender
Female 15 (35.7%) 13 (18%) 0.51
Male 27 (64.3%) 17 (23.6%)
Age
Female 55.2 ± 14.8 years 36.2 ± 12.1 years 0.001
Male 49.5 ± 16.3 years 35.8 ± 16.6 years 0.01
Figure 1 - A 54-year-old woman presenting with fever: (A) Her first axial unenhanced low dose chest computed tomography (CT) 
showed a focal rounded ground glass opacity (GGO) in the lateral basal segment of the left lower lobe. Acute phase reactan levels 
were abnormal except for troponin and C-reactive protein (CRP) on the first admission. Ferritin was 120 ng/mL, Lactate dehydrogenase 
(LDH) was 198 U/L, erythrocyte sedimentation rate (ESR) was 22 mm/h; (B) After 3 days, her follow-up CT scan showed progression 
of the GGOs as well as a ferritin of 144 ng/mL, LDH of 212 U/L, ESR of 28 mm/h, and CRP of 4 mg/L. Her troponin was normal.
Rev Inst Med Trop São Paulo. 2021;63:e51
Relationship between acute phase reactants and prognosis in patients with or without COVID-19 pneumonia
Page 5 of 8
Figure 2 - A 56-year-old male patient presenting with myalgia: (A) His first axial unenhanced low dose chest CT showed GGOs with 
consolidation in the basal segments of the right lower lobe. Furthermore, there were multifocal and multisegmenter GGOs in the left 
lower lobe. Acute phase reactan levels were abnormal except for the first troponin on admission. CRP was 172 mg/L, procalcitonin 
was 3,8 ng/mL and D-dimer was 231 ng/mL; (B) After 4 days, the follow-up CT scan showed progression of the GGOs in the left 
lower lobe with a regression of the consolidation in the right lower lobe. Moreover, CRP was 41 mg/L, procalcitonin was 0.7 ng/mL, 
ferritin was 310 ng/mL, LDH was 297 U/L, D-dimer was 242 ng/mL.
Table 3 - Laboratory findings (presented as mean values + or - standard deviations) of the patients with pneumonia (n=42) and 
without COVID-19 pneumonia (n=30). 
Acute phase reactans With pneumonia Without pneumonia p Normal range 
C reactive protein(mg/L) 69.9 + or - 92.1 (n=42) 12.5 + or - 26.4 (n=28) < 0.001 0-5
LDH (U/L) 294 + or - 160 (n=39) 215.1 + or - 81.2 (n=26) < 0.001 135-214
ESR (mm/h) 47.7 + or - 33.1 (n=35) 19.2 + or - 15.6 (n=13) 0.001 1–15
Fibrinogen (mg/dL) 512.6 + or - 222.1 (n=13) 350 + or - 153.1 (n=9) 0.04 200-400
Ferritin (ng/mL) 515.8 + or - 115 (n= 38) 100.7 + or - 74.9 (n=24) < 0.001 21-274
Procalcitonin (ng/mL) 0.25 + or - 0.67 (n=35) 0.05 + or - 0.02 (n=23) < 0.001 < 0.02
D-Dimer (ng/mL) 585 + or - 644 (n=36) 182 + or - 174.9 (n=28) < M0.001 < 250
Troponin I (ng/mL) 0.012 + or - 0.10 (n=42) 0.013 + or - (0.10) (n=30) 0.59 < 0.012
LDH = Lactate dehydrogenase; ESR = Erythrocyte sedimentation rate.
Table 4 - Laboratory finding of the mild cases (n=46) and the severe cases (n=26) of COVID-19 in this study. Note that not all the 
laboratory parameters were evaluated in all the patients. Laboratory results were presented as median (min-max) values. 
Acute phase reactans COVID-19 classification Median (min-max ) values p-value
C reactive protein (mg/L)* Mild (n=44) 5.15 ( 1-126) < 0.001
Severe (n=26) 44 (2-435)
LDH (U/L)* Mild (n=42) 203.5 (133-662) 0.014
Severe (n=23) 243 (144-908)
ESR (mm/h)† Mild (n=27) 25.7 + or - 15.0 0.001
Severe (n=21) 58.4 + or - 38.3
Fibrinogen (mg/dL)* Mild (n=14) 271(225-686) 0.041
Severe (n=8) 521 (329-1,032)
Ferritin (ng/mL)* Mild (n=41) 110 (7-1,157) 0.001
Severe (n=21) 310 (40-7,256)
Procalcitonin (ng/mL)* Mild (n=36) 0.05 (0.02-03) 0.02
Severe (n=22) 0.09 (0.04-3.8)
D-dimer (ng/mL)* Mild (n=42) 231.5 (73-2,323) 0.007
Severe (n=22) 318 (044-3,001)
Troponin I (ng/mL)* Mild (n=46) 0.10(0.1-0.9) 0.74
Severe (n=26) 0.09(0.04-3.8)
†Mean ± standard deviation; *Median (range); LDH = Lactate dehydrogenase; ESR = Erythrocyte sedimentation rate.
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DISCUSSION
SARS-CoV-2 is a novel coronavirus and generally 
causes mild respiratory disease1. However, it can cause 
severe pneumonia, which may progress to ARDS, shock, 
multiorgan failure and death. The mortality rates of 
COVID-19 pneumonia have been reported as 4.3%10, 11%3 
and 14.6%2 in recent publications. In addition, the severity 
of illness and mortality are increased by comorbidities, such 
as cerebrovascular disease, cardiovascular disease, HT and 
diabetes mellitus3. In our study, three of the 72 patients 
died, and the mortality rate was 4.1%, which is similar to 
the ones in the literature. 
RT-PCR is the recommended diagnostic test to detect 
SARS-CoV-2 RNA from the upper respiratory tract6. 
However, RT-PCR may generate false-negative results 
due to insufficient swab samples, which are collected from 
the oropharynx or nasopharynx11. False negative RT-PCR 
results may delay the diagnosis and the early treatment 
of patients, especially those with COVID-19 pneumonia, 
increasing the risk of community transmission11. Therefore, 
clinicians have begun to request chest CT scans to evaluate 
the lungs, especially in patients with suspected pneumonia, 
for the early diagnosis and treatment of the patients11. 
A bilateral distribution of GGOs with or without 
consolidation in the posterior and peripheral lung is the 
most common chest CT finding in patients with COVID-19 
pneumonia12. Pleural effusion, pericardial effusion, cavitation 
and mediastinal and/or hilar lymphadenopathy are rarely 
observed in COVID-1912. In our study, a bilateral multifocal 
peripheral and basal distribution of GGOs predominated 
as they were detected in 34 of 42 patients with COVID-19 
pneumonia. Pneumonia infiltration was detected in the left 
lung of three patients and the right lung of five patients.
APRs are critical for the early diagnosis, treatment, 
and for monitoring the progression of COVID-19. The 
acute-phase response to a tissue injury and inflammation is 
accompanied by a dramatic increase in the hepatic synthesis 
of plasma proteins known as APRs. The most important 
APRs include serum CRP, the ESR, LDH, fibrinogen, 
ferritin, procalcitonin and troponin7.
CRP is one of the best indicators of the acute phase 
response to inflammation. This serum protein is synthesized 
by hepatocytes and is classified as an acute-phase protein 
based on its increased serum concentration during 
inflammation and infection13. Normal levels of the CRP are 
inferior to 5 mg/L3. Tan et al.13 reported that CRP levels are 
positively-associated with CT severity scores in patients with 
COVID-19. They found that the area under the curve for CRP 
on the first visit is able to predict severe COVID‐19 and was 
0.87 (95% CI 0.10–1.00) considering a a cut-off of 20.42 
mg/L, with high sensitivity and specificity13. In addition, 
Zhang et al.14 revealed that there were no patients with 
severe clinical disease and lower CRP (< 20 mg/L) levels, 
whereas 84% of patients who had severe clinical disease, had 
higher CRP levels (> 150 mg/L). They reported that a higher 
CRP level was strongly associated with severe COVID-19 
pneumonia14. In our study, all CRP levels were higher than 5 
mg/L in 41 patients (80%) and 12 of these patients CRP levels 
were higher than 100 mg/L. CRP was significantly higher in 
patients with pneumonia than in those without pneumonia. In 
addition, the CRP value was significantly higher in patients 
with severe disease than in patients with mild disease. 
Therefore, our study supports the strong relationship between 
high CRP values and severe COVID‐19. 
The ESR is the sedimentation rate of red blood cells 
under certain conditions. Although the increase in the ESR 
in patients with COVID-19 cannot be fully explained, it is 
thought that an increase in the ESR occurs through changes 
in the erythrocyte forms and plasma characteristics13. 
Normal levels of the ESR are < 15 mm/h3. Tan et al.13 
reported that ESR levels were significantly elevated in 
the early stage, in patients with severe COVID‐19, while 
no significant difference in the chest CT scores could be 
identified between patients with severe and mild disease. 
In our study, ESR levels were higher than 15 mg/L in 
38 patients (79.1%) and three of these patients had ESR 
levels higher than 100 mg/L. ESR was significantly 
higher in patients with pneumonia than in those without 
pneumonia. In addition, the ESR value was significantly 
higher in patients with severe clinical disease than in those 
with mild disease.
LDH is found in all human cells, especially in myocardial 
and liver cells15. LDH secretion is triggered by necrosis of 
the cell membrane15. Studies in the literature identified that 
LDH could be a powerful predictive factor for the early 
recognition of lung injury16. The normal range of LDH is 
120-250 U/L3. Zhang et al.14 revealed that all patients whose 
LDH levels were higher than 720 U/L had severe disease, 
and a higher LDH activity was strongly correlated with 
severe COVID-19 pneumonia. In our study, LDH levels 
were higher than 250 U/L in 21 patients (32.3%). LDH value 
was significantly higher in patients with pneumonia than in 
those without pneumonia. In addition, the LDH value was 
significantly higher in patients with severe disease than in 
those with mild disease.
Ferritin is an iron storage protein and an inflammatory 
biomarker17. Serum ferritin is a marker of acute and chronic 
inflammation and is nonspecifically elevated in a wide range 
of inflammatory conditions17. Normal ferritin levels range 
from 21 to 274 ng/mL3. Although the exact mechanisms 
of hyperferritinemia and disease severity in patients with 
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COVID-19 remain unclear, it is thought that the stimulation 
of proinflammatory cytokines by SARS-CoV 2 triggers 
ferritin synthesis17. In addition, cellular damage secondary 
to inflammation can promote the leakage of intracellular 
ferritin, thus increasing serum ferritin levels17. Lin et al.17 
reported that higher serum ferritin predicted an increased 
risk of disease severity in patients with COVID-19. In this 
study, ferritin levels were higher than 274 ng/mL in 19 
patients (30%) and two of these patients had ferritin levels 
higher than 1,000 ng/mL. Moreover, ferritin levels were 
significantly higher in patients with pneumonia than in 
those without pneumonia. In addition, ferritin levels were 
significantly higher in patients with severe disease than in 
those with mild disease.
Procalcitonin is a 116-amino acid precursor of the 
hormone calcitonin18. There is increasing evidence on 
the usefulness of procalcitonin as a biomarker in lower 
respiratory tract infections7. It has been reported that 
procalcitonin is remarkably useful for the early diagnosis 
of bacterial pneumonia, guiding antibiotic therapy and 
predicting the patients who have a higher risk of developing 
complications7. Normal levels of procalcitonin are 
< 0.5 ng/mL. Procalcitonin rarely exceeds 0.5 ng/mL in 
viral infections1. Recent studies have demonstrated that 
procalcitonin levels positively correlate with the severity of 
COVID-192,14,19. In addition, Lippi et al.20 reported a meta-
analysis and showed that increased procalcitonin levels are 
related to an approximately 5-fold higher risk of severe 
COVID-19. Hu et al.18 revealed that the procalcitonin value 
was 4 times higher in patients with severe disease than in 
those with moderate disease, and 8 times higher in patients 
with critical disease than in patients with moderate disease. 
In addition, they reported that a progressive increase in the 
procalcitonin level is associated with poorer prognosis. 
Here, procalcitonin levels were higher than 0.05  ng/mL 
in 34  patients (58.6%) and 11 of these patients had 
procalcitonin levels higher than 0.10 ng/mL. Furthermore, 
procalcitonin levels were significantly higher in patients with 
pneumonia than in those without pneumonia. In addition, 
procalcitonin levels were significantly higher in patients with 
severe disease than in patients with mild disease.
D-dimers are protein products of the cross-linked 
fibrin break down that are present in the blood of most 
healthy individuals in only insignificant amounts21. 
D-Dimer and fibrinogen are sensitive indicators of 
coagulation dysfunctions. Increased D-dimer levels indicate 
hypercoagulability and secondary fibrinolysis21. High levels 
of D-dimer have been reported to determine the severity 
of pneumonia and the early diagnosis of sepsis in these 
patients1. Long et al.21 reported that coagulation disorders 
occur in the early stage of COVID-19 and that an increase in 
D-dimer and fibrinogen levels were significantly correlated 
with the parenchymal progression to pneumonia in the 
chest CT. They also reported that fibrinogen and D-dimer 
levels were significantly elevated in seriously ill COVID-19 
patients21. In this study, D-dimer levels were significantly 
higher in patients with pneumonia than in those without 
pneumonia. D-dimer levels were higher than 250 ng/mL in 
36 patients (56%) and four of these patients had D-Dimer 
levels higher than 1,000 ng/mL. In addition, D-dimer levels 
were significantly higher in patients with severe disease 
than in those with mild disease. Moreover, pulmonary 
embolism was suspected in a patient with a high D-dimer 
level (676 ng/mL) who was treated in the ICU due to the 
development of dyspnea. Pulmonary CT angiography was 
performed, and the findings showed no pulmonary emboli 
but did show the presence of pneumonia infiltration.
It has been reported that increased troponin I levels 
in COVID-19 patients are associated with an adverse 
prognosis and mortality22. Normal levels of the cardiac 
troponin are less than 0.012 ng/mL23. Elevated troponin I 
levels can be explained by several mechanisms, including 
viral myocarditis, cytokine-induced myocardial damage, 
microangiopathyand coronary artery disease, although the 
related mechanisms have not been proven22. It is thought 
that the renin-angiotensin-aldosterone system is disrupted in 
patients with COVID-19, and decreased ACE2 is associated 
with cardiovascular injuries22. In this study, troponin I 
levels were higher than 0.012 ng/mL in five patients, but 
there were no statistically significant differences between 
troponin values in patients with and without pneumonia. in 
our study. Furthermore, there was no statistically significant 
difference in patients with severe disease than in patients 
with mild disease.
The limitations of our study include the low number of 
patients. In addition, laboratory tests were not performed 
for every patient. They were performed only in cases in 
which they were deemed necessary. This situation reduced 
the sample size.
CONCLUSION
In conclusion, CRP, LDH, ESR, ferritin, and D-dimer 
were associated with severe COVID-19 pneumonia. These 
biomarkers can be used to evaluate the prognosis, to predict 
the clinical course, and to help the management and the 
treatment of these patients. 
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